Song will focus on web applications development and solutions to help drive SilcsBio’s continued growth
September 28, 2021, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced the hiring of KC Song as Full Stack Developer.
Song joins the SilcsBio team as an experienced web application development professional and business leader whose work will center on developing web applications solutions for SilcsBio.
In his most recent role, Song was founder and CEO of Jayeon Soft, leading web application development and app solutions using Data Science APIs and video/audio control features. As part of his work leading Jayeon Soft, Song developed a multi-language translation platform for Glocalize (a Netflix Partner).
In addition, Song was CTO at Wellxecon, a medical startup where he built an individual health age prediction platform, and led development of the business requirements of application logics with regard to health age, health scores and medical expenses predictions for a 10-year period. He also worked as a Team Manager at DACON and was Senior Manager of an overseas business team at Hyundai Development Company.
“KC’s web app development experience and immersion in the startup world give our team significant skill sets for our companies to leverage,” said Ken Malone, CEO of SilcsBio. “Plus, KC is a great team player and leader – and we’re excited to bring him and his energy and ideas on board to help our company continue to grow.”
Song graduated from Yonsei University Seoul with a B.S. in Computer Science and Industrial System Engineering. He also earned academic credits as an exchange student at Hong Kong Polytechnic University and at the University of Oxford.
SilcsBio, LLC offers a platform technology that advances computational drug design applications through detailed protein mapping that accounts for flexibility and solvation and enables highly efficient ligand binding evaluation, virtual screening, and more. SilcsBio software and services span from target protein mapping and analysis through lead optimization and offers key
insights for biological therapeutic formulations. The proprietary software unlocks hidden binding hotspots of target proteins and reveals the preferred ligand chemistries at those sites to rapidly guide the drug design process. SilcsBio most recently announced a partnership with Aikido Pharmaceuticals. Learn more: www.silcsbio.com
(410) 401-9794, ext. 701